Fortrea Holdings Inc.
Financials
Valuation Metrics
Fortrea Holdings Inc.'s Market Cap is $1.79B. At end of 2025 it was $1.57B. Ranked #2113 of 3,111 in US market (top 68%), #817 of 1,445 on NASDAQ (top 57%), #145 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.79B | US#2,113/3,111 Sec#145/269 |
| Revenue | $2.68B | US#1,310/3,111 Sec#37/269 |
| Net Income | $-85M | US—/3,111 Sec—/269 |
| Total Assets | $2.71B | US#1,881/3,111 Sec#48/269 |
| Net Assets | $524M | US#2,225/3,111 Sec#108/269 |
| Employees | 13,871 | US#489/3,111 Sec#13/269 |
| Value | ||
| P/B | 3.42x | US#1,843/3,111 Sec#106/269 |
| P/S | 0.67x | US#408/3,111 Sec#8/269 |
| EV/EBITDA | 20.97x | US#1,925/3,111 Sec#56/269 |
| FCF Yield | 8.41% | US#697/3,111 Sec#24/269 |
| Profitability | ||
| ROE | -16.25% | US#2,484/3,111 Sec#96/269 |
| ROA | -3.14% | US#2,448/3,111 Sec#88/269 |
| Op. Margin | 0.41% | US#2,405/3,111 Sec#87/269 |
| Revenue Growth | -4.52% | US#2,503/3,111 Sec#137/269 |
| Financial Health | ||
| Debt Ratio | 417.91% | US#2,320/3,111 Sec#233/269 |
| Total Debt | $80M | US#2,471/3,111 Sec#130/269 |
| FCF | $151M | US#1,502/3,111 Sec#52/269 |
| Cash | $169M | US#1,857/3,111 Sec#134/269 |
| Current Ratio | 0.96x | US#2,336/3,111 Sec#264/269 |
| Net Debt/EBITDA | -1.09x | US#293/3,111 Sec#21/269 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,111 Sec—/269 |
| Payout Ratio | 0.00% | US—/3,111 Sec—/269 |
| Performance | ||
| 1Y Return | 246.89% | US#73/3,111 Sec#25/269 |
| 1M Return | 9.61% | US#553/3,111 Sec#33/269 |
| From 52W High | -11.45% | US#1,028/3,111 Sec#61/269 |
| 1Y MDD | -51.47% | US#2,458/3,111 Sec#191/269 |
| Trading | ||
| Volume | 3,104,799 shares | US#982/3,111 Sec#89/269 |
| Trading Value | $58M | US#1,654/3,111 Sec#112/269 |
| Per Share | ||
| EPS | $-10.81 | US—/3,111 Sec—/269 |
| BPS | $6.05 | US#2,129/3,111 Sec#115/269 |
Company Info
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.